NUCYNTA Drug Patent Profile

When do Nucynta patents expire, and what generic alternatives are available?

Nucynta is a drug marketed by Collegium Pharm Inc and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tapentadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nucynta

A generic version of NUCYNTA was approved as tapentadol hydrochloride by NOVITIUM PHARMA on January 26^th, 2026.

Summary for NUCYNTA

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	45
Clinical Trials:	6
Drug Prices:	Drug price information for NUCYNTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUCYNTA
What excipients (inactive ingredients) are in NUCYNTA?	NUCYNTA excipients list
DailyMed Link:	NUCYNTA at DailyMed

See drug prices for NUCYNTA

Recent Clinical Trials for NUCYNTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Grünenthal GmbH	Phase 4
Ortho-McNeil Janssen Scientific Affairs, LLC	Phase 3
Grünenthal GmbH	Phase 3

See all NUCYNTA clinical trials

Pharmacology for NUCYNTA

Drug Class	Opioid Agonist
Mechanism of Action	Opioid Agonists

Paragraph IV (Patent) Challenges for NUCYNTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUCYNTA	Oral Solution	tapentadol hydrochloride	20 mg/mL	203794	1	2013-12-20
NUCYNTA	Tablets	tapentadol hydrochloride	50 mg, 75 mg, and 100 mg	022304	4	2012-11-20

US Patents and Regulatory Information for NUCYNTA

NUCYNTA is protected by zero US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012		DISCN	Yes	No
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-005	Aug 25, 2011		RX	Yes	Yes	11,344,512*PED				Y
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-003	Nov 20, 2008	AB	RX	Yes	Yes
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-001	Nov 20, 2008	AB	RX	Yes	No
Collegium Pharm Inc	NUCYNTA ER	tapentadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200533-002	Aug 25, 2011		RX	Yes	No	11,344,512*PED				Y
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-003	Nov 20, 2008	AB	RX	Yes	Yes

Expired US Patents for NUCYNTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-002	Nov 20, 2008	6,071,970
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-003	Nov 20, 2008	RE39593
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	SOLUTION;ORAL	203794-001	Oct 15, 2012	6,071,970
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-001	Nov 20, 2008	6,071,970
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-003	Nov 20, 2008	6,071,970
Collegium Pharm Inc	NUCYNTA	tapentadol hydrochloride	TABLET;ORAL	022304-001	Nov 20, 2008	RE39593

International Patents for NUCYNTA

See the table below for patents covering NUCYNTA around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	953523
Portugal	743853
China	1077566
Colombia	4410179	COMPUESTOS DE 1-FENIL-3-DIMETILAMINO-PROPANO CON EFECTO FARMACOLOGICO
Germany	4426245
Australia	6112596

Supplementary Protection Certificates for NUCYNTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0693475	PA2011007,C0693475	Lithuania		PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819
1439829	99 1-2011	Slovakia		PRODUCT NAME: TAPENTADOL; NAT. REGISTRATION NO/DATE: 65/0667-0674/10-S, 65/090-0697/10-S 20101012; FIRST REGISTRATION: DE 75043-75048.00.00, 76261-76270.00.00 20100819
0693475	CA 2010 00036	Denmark
0693475	12C0016	France		PRODUCT NAME: TAPENTADOL SOUS FORME DE SA BASE LIBRE OU SOUS FORME D'UN DE SES SELS D'ACIDES ACCEPTABLES DU POINT DE VUE PHYSIOLOGIQUE; NAT. REGISTRATION NO/DATE: NL40884 20111003; FIRST REGISTRATION: DE - 76261.00.00 20100819
0693475	2011/010	Ireland		PRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819
0693475	C300541	Netherlands		PRODUCT NAME: TAPENTADOL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TAPENTADOL HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 110721-110724 RVG 110728-110731 20120316; FIRST REGISTRATION: DE 75043.00.00 - 75045.00.00, 75046.00.00, 76261.00.00 - 76270.00.00 20120819

Market Dynamics and Financial Trajectory for NUCYNTA

Last updated: February 19, 2026

What is the current market position of NUCYNTA?

NUCYNTA (tapentadol) is a prescription opioid analgesic indicated for pain management, including severe chronic pain and neuropathic pain. It is marketed by Collegium Pharmaceutical. Sales peaked in the mid-2010s but have declined recently due to regulatory shifts, generic competition, and evolving prescribing patterns.

Globally, the drug competes primarily with other opioids like oxycodone and tramadol. North America remains the largest market, driven by high opioid prescription rates, despite increasing restrictions on opioid dispensing.

How has the market size evolved over recent years?

In 2020, the global opioid analgesics market was valued at approximately USD 11 billion; NUCYNTA captured an estimated USD 300 million to USD 350 million. The U.S. accounted for roughly 75% of this revenue.

Market growth has slowed amid the opioid crisis, increasing scrutiny and regulation. Between 2015 and 2020, sales CAGR (compound annual growth rate) averaged just below 2%. Recent trends show a plateau or slight decline in sales volume due to:

• More stringent prescribing guidelines
• Growing utilization of non-opioid pain therapies
• Prescriber and patient caution stemming from abuse concerns

What are the major factors influencing revenue and market share?

Regulatory Environment

Regulatory agencies such as the FDA and DEA tighten controls on opioids, affecting NUCYNTA sales through restricted prescribing and dispensing limits. In 2018, the FDA issued guidelines to decrease opioid prescriptions by 30% over five years.

Patent and Generic Competition

The original patent for NUCYNTA expired in 2018. Since then, multiple generics entered the market, reducing the brand's market share and price. The entry of generics typically leads to a 65-75% reduction in revenue per unit.

Prescriber and Patient Trends

Physicians increasingly favor non-opioid options for pain management. Routes such as NSAIDs, anticonvulsants, and behavioral therapies gain traction, diminishing NUCYNTA's prescribing rates.

Policy and Reimbursement

Insurance companies and government programs emphasize alternative therapies and implement prior authorization requirements, limiting access for patients.

Emerging Market Penetration

Growth potential exists in regions outside North America but remains constrained by lower opioid acceptance, regulatory barriers, and reimbursement challenges.

What are the financial projections for NUCYNTA?

Revenue Forecasts

Based on current market trends and competitive landscape, NUCYNTA revenue projections are:

Year	Estimated Revenue (USD million)	Growth Rate (%)
2022	180	-8
2023	165	-8.3
2024	150	-9.1
2025	135	-10

Sources of decline include continued generic erosion, regulatory pressures, and decreasing prescriber preference.

R&D and Launch Prospects

Future revenue growth hinges on new formulations or indications. Collegium has explored extended-release formulations and alternative delivery methods, potentially offering improved safety profiles. However, clinical development timelines extend over 3-5 years, with uncertain market acceptance.

Pricing Dynamics

Average wholesale unit prices for branded NUCYNTA (pre-generic) around USD 10–USD 15 per pill. Post-generic entry, prices typically fall below USD 3–USD 5 per pill, affecting revenue margins.

Profitability and Investment Outlook

Gross margins declined from approximately 60% pre-generic to near 25–30% post-generic. Cost-saving measures and pipeline development are critical to maintaining profitability.

Comparative Analysis with Similar Drugs

Drug	Market Share (2020)	Patent Status	Annual Revenue (USD million)	Typical Price per Dose
NUCYNTA	8-10%	Expired (2018)	300-350	USD 10–USD 15
OxyContin	15-18%	Still valid	USD 400–USD 500	USD 20–USD 25
Tramadol	Widely used, generic	No patent	USD 150–USD 200	USD 1–USD 3

What are the risks and opportunities?

Risks

• Declining efficacy as pain management standard shifts away from opioids.
• Heightened regulatory scrutiny leading to decreased prescriptions.
• Increased competition from newer non-opioid therapies.
• Pricing erosion due to generic entries.

Opportunities

• Development of abuse-deterrent and extended-release formulations.
• Expansion into emerging markets with less mature regulation.
• Combining NUCYNTA with other agents for multi-modal pain management.
• Enabling digital health tools to monitor usage and adherence.

Key Takeaways

• NUCYNTA's market share has declined due to patent expiry and regulatory challenges.
• Revenue is forecasted to decrease annually by approximately 8–10% over the next three years.
• The drug faces stiff competition from generics and alternative therapies.
• Growth prospects depend on pipeline innovation and market expansion outside North America.
• Profitability has been compressed by lower prices and reduced prescribing.

FAQs

1. Will NUCYNTA regain market share?
Unlikely without new formulations or indications. The opioid landscape favors diversified pain management strategies.

2. Are there any new formulations under development?
Collegium has investigated extended-release and abuse-deterrent versions; market approval timelines extend over 3-4 years with uncertain adoption.

3. What markets outside the U.S. show potential?
Europe and parts of Asia show growth opportunities, but regulatory hurdles and low acceptance of opioids limit rapid expansion.

4. How do regulatory changes affect revenue?
Tighter FDA and DEA controls result in fewer prescriptions, directly reducing revenue and market share.

5. What is the outlook for generic competition?
Generic versions dominate post-patent expiry, accounting for over 90% of prescriptions, exerting downward price pressure on brand sales.

---

References

1. IMS Health. (2021). Global opioid market report.
2. U.S. Food and Drug Administration. (2018). Guidelines on opioid prescribing.
3. Collegium Pharmaceutical Inc. Annual Report. (2022).
4. Statista. (2022). Opioid analgesics market insights.
5. FDA. (2022). Drug approval and patent data.

[1] Source: IMS Health (2021).